Introduction
The tumor suppressor p53 has been described as a 'guardian of the genome' because of its crucial function in coordinating cellular responses to diverse stresses such as DNA damage, hypoxia, and oncogenic activation (Lane, 1992; Levine, 1997; Giaccia and Kastan, 1998) . It has been found that p53 activity is either disabled or attenuated in the majority of human cancers. When stabilized and activated, p53 initiates a transcriptional function that can trigger cell-cycle arrest, apoptosis, cellular senescence, or aging (Vogelstein et al., 2000; Vousden and Lu, 2002) .
Alternate reading frame (ARF) protein, also known as p19ARF in mouse and p14ARF in human, is a tumor suppressor encoded by the alternative reading frame of the INK4a/ARF locus (Quelle et al., 1995) . This locus (also known as CDKN2A in human) is among the most frequently disrupted sites resulted from chromosomal deletion, mutation, or epigenetic silencing in a large number of human tumors (Ruas and Peters, 1998; Sharpless and DePinho, 1999) . Activation of ARF by hyperproliferative oncogenic stimuli, including c-Myc, E1A, E2F1, Ras, or b-catenin, suppresses the growth of the affected cells by promoting cell growth arrest, senescence, or apoptosis (Sherr, 2001; Lowe and Sherr, 2003; Sharpless, 2005) . Most, if not all, of these cellular responses are mediated through p53. Indeed, ARF stabilizes and activates p53 by directly interacting with its major negative regulator Mdm2, thereby inhibiting the ubiquitin ligase activity of Mdm2 and abolishing the inhibitory effect of Mdm2 on p53 (Kamijo et al., 1998; Pomerantz et al., 1998; Honda and Yasuda, 1999) . Intriguingly, the mechanism by which ARF modulates Mdm2-p53 pathway is now appearing to be more complex than earlier conceptualized. In the Mdm2-null cell, ARF can activate the p53 through binding and inhibiting ARF-BP1/Mule, a newly identified E3 ubiquitin ligase for p53 (Chen et al., 2005) . Moreover, increasing number of studies are providing evidence that ARF has p53-independent functions (Weber et al., 2000; Tago et al., 2005; Ha et al., 2007) .
Myc-interacting zinc-finger protein-1 (Miz-1), an 803 amino-acid (aa) protein belonging to the poxvirus and zinc-finger (POZ), or Broad complex, Tramtrack, Bric ab rac zinc-finger transcription factor family, has been found as a Myc-interacting protein Schneider et al., 1997) . POZ domain is a highly conserved domain of approximately 100 aa involved in protein-protein interactions and is present in over 200 proteins (Bardwell and Treisman, 1994; Albagli et al., 1995; Collins et al., 2001) . POZ proteins with zinc fingers often exist in transcriptional repression complexes (and occasionally in transcriptional activation complexes) and they generally interact with DNA through their zinc-finger motifs to induce chromatin modification and/or restructuring. POZ proteins with zinc fingers have also been implicated in many other biological processes including DNA damage response, cell-cycle progression, and numerous developmental events (Kelly and Daniel, 2006) . Free Miz-1 binds to the initiator element (Inr), a transcriptional initiation motif (5 0 -YYANT/ACY-3 0 , Y¼ pyrimidine, and N ¼ any nucleotide) surrounding the mRNA start site, of several genes that are repressed by Myc and activates a transcriptional response that suppresses cell proliferation. Myc is recruited to these sites and represses transcription through physical interaction with Miz-1 and Max . On the other hand, by interaction with the C-terminal helix-loop-helix domain of Myc, Miz-1 stabilizes the highly unstable protein Myc (Salghetti et al., 1999) .
In this study, we identified Miz-1 as a new partner protein of ARF and their interaction is mediated by the zinc-finger domain of Miz-1. We also found that Miz-1 could diminish the binding of p53 to its target promoter by directly binding to p53 DNA-binding domain (DBD), resulting in the repression of p53 transcriptional activity. Intriguingly, both p53 and ARF were found to interact with the zinc-finger domain of Miz-1, indicating that there exists a competitive binding between ARF and p53 to Miz-1 in regulating gene transcription. In addition, Miz-1/p53 interaction results in the decreased p53-dependent transcriptional activity, whereas interaction of ARF and Miz-1 antagonizes the repression of Miz-1 on p53-dependent transcription. Thus, we have provided a novel regulatory pathway regarding p53 transcriptional control in addition to the wellestablished ARF-Mdm2-p53 pathway. Our finding elucidates an alternative pathway ARF-Miz-1-p53, by which p53-dependent transcription can be independent of Mdm2.
Results

Miz-1 interacts with ARF
In an attempt to identify new in vivo targets of p14ARF, we performed a yeast two-hybrid screen using full-length human ARF as bait. From 1.0 Â 10 7 yeast transformants screened, 26 putative positive clones were identified. Among them, one clone encoding a fragment of Miz-1 (aa 496-803), as confirmed by sequence determination, was found to be an ARF-interacting protein (Figure 1a) . To determine whether Miz-1 associates with ARF in mammalian cells, a co-immunoprecipitation (Co-IP) experiment was performed. As shown in Figure 1b , transfected green fluorescent protein GFP-ARF, but not GFP alone, in HeLa cells was co-immunoprecipitated by anti-Miz-1 antibody (lane 2 vs lane 1, middle panel), indicating that Miz-1 can bind to ARF. Consistently, as shown by a reciprocal Co-IP experiment (Figure 1c ), endogenous Miz-1 was co-immunoprecipitated by an anti-ARF antibody, but not with an irrelevant control antibody (lane 3 vs lane 2). To determine the percentage of Miz-1 bound to ARF in the cell, we used anti-ARF to immunoprecipitate endogenous Miz-1 and nucleophosmin/B23 simultaneously in H1299 cell line (ARF þ /þ , p53À/À), and compared their interactions by immunoblotting. The intensity of immunoprecipitate was quantified by the ImageJ software. As shown in Figure 1c , about 50% of endogenous Miz-1 binds to ARF, whereas just about 4.1% nucleophosmin/B23 interacts with ARF, which is consistent with earlier report by Dawn E Quelle laboratory, in which they found that only a minor percentage of NPM was coprecipitated with ARF from Narf6 cell lysates (Korgaonkar et al., 2005) . To define the region of Miz-1 responsible for interacting with ARF, a series of Miz-1 truncation mutants were constructed (Figure 2a, upper panel) . These Miz-1 truncation mutants were individually co-expressed in H1299 cells with Flag-ARF and tested for their interaction by Co-IP assay (Figure 2a , lower part). We found that mutants of Miz-1, which contain either the zinc-finger region ZF1-12 or ZF13, were able to associate with ARF (lanes 4, 7, 9, 10, and 11). In contrast, mutants of Miz-1 that have both ZF1-12 and ZF13 deleted were unable to interact with ARF (lanes 3, 5, 6, and 8). Thus, Miz-1 may bind to ARF through its two separate zinc-finger regions. This result is consistent with the results from the yeast two-hybrid screen, in which a fragment of Miz-1 containing the greater part of ZF1-12 and an intact ZF13 region was found to interact with ARF ( Figure 1a) . Reciprocally, we mapped the region of ARF that interacts with Miz-1 using a panel of ARF truncation mutants ( Figure 2b ). As shown in Figure 2b , ARF lacking N-terminal 1-14aa was able to interact with Miz-1 (lane 3), yet the N-terminal 14aa, known as ARF's major Mdm2-binding domain (Midgley et al., 2000) , failed to bind to Miz-1 (lane 2). As Kriwacki and coworkers had defined additional two consecutive short regions to which Mdm2 was able to bind within the acidic region of ARF (Bothner et al., 2001) , we, therefore, are unable to conclude that Miz-1 and Mdm2 show non-overlapping binding to ARF.
Miz-1 suppresses p53 transcriptional activation
It has been reported that ARF was able to suppress aberrant cell growth in response to oncogenic activation, at least in part, by inducing p53 tumor suppressor function through binding to Mdm2. To investigate whether the Miz-1/ARF interaction has a function in the ARF-p53 pathway, we used a dual luciferase reporter assay. Plasmid pGL3-13-p53-Luc, which contains an array of 13 consecutive p53-binding sites upstream of the luciferase reporter gene, or pGL3-Bax-Luc, which contains the p53-binding site of the bax promoter, was used to evaluate the p53 transcriptional activity. As shown in Figures 3a and b , increasing amount of p53 resulted in marked increases in transactivation (TA) for both the p53-responsive synthetic promoter and Bax promoter ( Figure 3a , lanes 2-3; Figure 3b , lanes 2-3). However, when increasing amount of Miz-1 was co-expressing with constant level of p53 in H1299 (p53À/À, ARF þ / þ ) cells, transactivition by p53 was notably declined (Figure 3a , lanes 4-5; Figure 3b , lanes 4-5), indicating that Miz-1 inhibits p53-dependent transcriptional activation. As control, in the absence of p53, Miz-1 alone caused little, if any transactiviation for both the p53-responsive synthetic promoter ( Figure 3a , lane 6) or Bax promoter (Figure 3b, lane 6 ). At present, we do not know why Miz-1 alone showed some degree of TA for Bax promoter (Figure 3b , lane 6), but it could be due to a very low level of toxicity caused by Miz-1 expression to the cells (unpublished data). In addition, although Miz-1 suppressed the transcriptional activity of p53, the p53 protein level remained unchanged (Figures 3a and b , lower panels, lane 4 vs lane 5). To further validate the conclusion that endogenous Miz-1 may suppress the transcriptional activation of p53, Miz-1 was knocked down by shRNA-mediated gene silencing using retroviral plasmid pshRNA-Miz-1. The successful knockdown of Miz-1 was confirmed by both reverse transcription polymerase chain reaction (RT-PCR) and immunoblotting (Figures 3c and d, lower parts) . As shown in Figure 3d , knockdown of Miz-1 resulted in approximately 3.0-3.5-fold increase in the TA of both the Bax promoter and the synthetic p53-responsive elements by p53, indicating that endogenous Miz-1 inhibits the p53 transcriptional activation. ARF stabilizes p53 by binding and inhibiting Mdm2, which is an E3 ligase for p53. To check whether the suppression of p53 transcriptional activity by Miz-1 is due to a reduced intracellular p53 level, we tested the ability of Miz-1 on repressing p53 TA in Mdm2-deficient cells. As shown in Figure 3e , repression of p53 TA by increasing amount of Miz-1 still occurred in p53À/À mdm2À/À MEF cells expressing consistent level of p53. A similar pattern was observed in the absence of Mdm2 (lanes 2-4) as when it was present (Figures 3a and b, lanes 4-5) , thus indicating that the suppression effect of Miz-1 on p53 transcription does not require Mdm2. To examine whether ARF is required for Miz-1-mediated p53 transcriptional suppression, A549 cells that is naturally deficient in ARF were used. As shown in Figure 3f , in the absence of doxorubicin (Dox) treatment, both the endogenous p53 and the p53-regulated TA were low. Even then, however, Miz-1 showed some repression on p53 transcription (lanes 1-3). When Dox was added, the level of p53 was increased (middle panel, lanes 4-6 vs lanes 1-3), Miz-1 caused a significant repression of p53-dependent TA in a dose-dependent manner (lanes 4-6). These results indicate that ARF is not required for Miz-1 in repressing p53-targeted gene transcription either. Role of Miz-1 in ARF-p53 pathway L Miao et al
Miz-1 interacts with the DBD of p53 through its zinc-finger domain to diminish p53 binding to p53-target promoter As shown above, Miz-1 is able to suppress p53-induced transcriptional activation, yet its suppression does not seem to be due to p53 destabilization, so a novel mechanism must be involved. We first examined whether Miz-1 physically associates with p53 to interfere the transcriptional activity of p53. A Co-IP assay was performed as shown in Figure 4a , GFP-tagged Miz-1, but not GFP alone, could be co-immunoprecipitated by Flag-p53 (lane 4 vs lane 3). Reciprocally, GFP-tagged p53, but not GFP alone, was able to be co-immunoprecipitate with Flag-tagged Miz-1 (lane 8 vs lane 7). These results showed that p53 and Miz-1 interact with each other. To examine the percentage of Miz-1 that is bound to p53, we used p53 antibody to perform Co-IP to precipitate the endogenous protein Miz-1 and Mdm2. As shown in Figure 4b , approximately 23% of Mdm2 and 56.5% Miz-1 protein in HepG2 cells were precipitated by p53 antibody. Tumor suppressor p53 can functionally be divided into three domains: TA domain at its N-terminus, DBD in the center, and polyfunctional domain at its C-terminus. To further determine which domain of p53 is involved in its interaction with Miz-1, H1299 cells were co-transfected with GFP-Miz-1 and either wild-type (wt) p53, mutant p53 lacking transactivation domain (p53DTA), or mutant p53 missing DNA-binding domain (p53DDBD), and Co-IP assay was then used to check their interactions. As shown in Figure 4c , GFP-Miz-1 failed to immunoprecipitate with p53DDBD (lane 6). Reciprocally, p53DDBD failed to co-immunoprecipitate with GFPMiz-1 using an anti-GFP antibody ( Figure 4c , lane 12), suggesting that the DBD of p53 may be involved in its interaction with Miz-1. To define which region of Miz-1 was involved in interaction with p53, each Miz-1 deletion mutant indicated in Figure 4d (left part) was used to co-express with Flag-p53 and tested for their interactions. As shown in Figure 4d (right part) Miz-1 protein containing region ZF1-12, ZF13, or both was found to bind p53 (lanes 6, 7, 8, and 9) . In contrast, Miz-1 lacking both ZF1-12 and ZF13 was unable to bind to p53 (lanes 2, 3, and 4), suggesting Miz-1 zinc-finger domain ZF1-12 or ZF13 is both sufficient and required for p53 binding. It is worthwhile to note that as we showed above, ARF seems to interact with the Miz-1 zinc-finger region as p53 does, which reminds us to presume that Role of Miz-1 in ARF-p53 pathway L Miao et al there may exist a competition between ARF and p53 in binding to Miz-1 (see next section for details). To further investigate whether p53/Miz-1 interaction is responsible for the suppression of p53-induced transcription, luciferease activities were compared among cells exogenously expressing wt-p53, p53DTA, or p53DDBD in the presence and absence of Flag-Miz-1. As shown in Figure 5a , in the absence of Miz-1, TA by either p53DTA or p53DDBD was greatly decreased compared with that by wt-p53 (lanes 2, 3 vs lane 1), and this was expected, as neither p53DTA nor p53DDBD was capable of promoting transcription. In the presence of Miz-1, wt-p53 TA ability was obviously reduced as a result of Miz-1-mediated suppression (lane 4 vs lane 1); however, the residual Quantification of luciferase activities and calculations of relative ratios were performed manually using a luminometer. Each histogram bar represents the mean±s.e.m. of three independent transfection experiments (each assayed in duplicate). Error bars indicate s.d. * denotes Po0.05 and **Po0.01. The expression of transfected plasmids was analyzed by western blotting shown below the histograms. (c) H1299 cells were transfected with either pshRNA or pshRNA-Miz-1 for depleting the endogenous Miz-1.The pshRNA plasmid includes the GFP gene and can be detected under fluoroscope. After 48 h of transfection, pshRNA-or pshRNA-Miz-1-transfected cells were picked and pooled for further culture. Total RNA was extracted from these resultant shRNA stable clones and RT-PCR was subsequently performed. b-actin was used as a loading control. (d) H1299 cells that stably expressing transfected pshRNA or pshRNA-Miz-1 were individually cotransfected with 500 ng of reporter plasmid pGL3-13-p53-Luc or pGL3-Bax-Luc in combination with fixed amount of p53 plasmid. Ten nanograms of renilla vector pRL-CMV was used as a transfection internal control. Quantification of luciferase activities and calculations of relative ratios were performed manually with a luminometer. The results are mean ± s.e.m. of triplicates. * denotes Po0.05. The expression of transfected plasmids was analyzed by western blotting as shown below the histograms. (e) Mdm2 is not required for Miz-1-mediated p53 TA suppression. MEF (p53À/À, Mdm2À/À) cells were transfected with a fixed content of p53 (100 ng) and an increasing amount of Miz-1 (0 ng, 100 ng, 200 ng), combined with 500 ng reporter plasmid pGL3-13-p53-Luc. Twenty-four hours later, transfected cells were further incubated with MG132 (25 mg/ml) for another 5 h. Ten nanograms of renilla vector pRL-CMV were used as a transfection internal control. The results are mean±s.e.m. of triplicates (*Po0.05, **Po0.01). The expression of transfected plasmids was analyzed by western blotting shown below the histograms. (f) ARF is not required for Miz-1-mediated p53 TA suppression. A549 (p53 þ / þ , ARFÀ/À) cells were transfected with an increasing concentration of Miz-1 in the presence or absence of the treatment of 4 mg/ml Dox, which allows for the activation of endogenous p53. A total of 500 ng of pGL3-13-p53-Luc was transfecterd into A549 cells as reporter and 10 ng of renilla vector pRL-CMV as a control. Calculation of luciferase activity was performed as in (e). The expression of transfected plasmids was analyzed by western analysis shown below the histograms. Role of Miz-1 in ARF-p53 pathway L Miao et al p53DDBD TA remained unaffected (lane 6 vs lane 3), and this could be due to the inability of Miz-1 in binding to p53DDBD (Figure 4c , lanes 6 and 12). Although TA of p53 synthetic promoter elements by p53DTA is marginal in the absence of Miz-1, it showed some degrees of repression on p53 transcription in the presence of Miz-1 (Figure 5a , lane 5 vs lane 2), the reason for that is not clear at present. It is reasonable to expect that Miz-1/p53 interaction abolishes the ability of p53 to bind to DNA, as p53 DBD domain is occupied by Miz-1 by Miz-1/p53 interaction. To validate this hypothesis, we performed a chromatin immunoprecipitation (ChIP) assay using H1299 cells (p53À/À) that individually expressed Flagempty vector, Flag-p53, or Flag-p53 plus Flag-Miz-1 to test two endogenous authentic p53-target promoters, namely Bax and Puma promoters. As shown in Figure 5b , only anti-p53 antibody, but not irrelevant anti-GFP antibody, was able to precipitate p53-bounded promoter elements, which were subsequently PCR amplified (lanes 8-10 vs lanes 5-7). More importantly, the products of enriched PCR fragments from either Bax or Puma promoter were notably reduced in the co-presence of p53 and Miz-1 than in beads, yet b-actin gene will not be correlated with the antibody against p53. Moreover, it also reflects the sample amounts used in assay (Hershko and Ginsberg, 2004) . To further confirm the effect of Miz-1 on p53 transcriptional activity, we transfected HepG2 cells (p53 þ / þ ) with shMiz-1 vs control and induced p53 expression with DNA damage reagent Dox (5 mg/ml), followed by examining the expression of p53-target genes Bax and Puma, and analyzing the p53-binding activity to the Bax and Puma promoters using ChIP assay. As show in Figures 5c and d, when p53 Miz-1 competitively binds to ARF and p53 in regulating p53-mediated transcription The above results revealed that Miz-1 interacts with p53 through its DBD, and thus to repress p53 transcriptional activity by eliminating p53 binding to its target promoter, and in addition, ARF is not required for this Miz-1-mediated repressional effect on p53. We then asked what the function for ARF/Miz-1 association is. Miz-1 is able to bind ARF and p53 through its zincfinger regions, which made us to assume that ARF may compete with p53 for interacting with Miz-1. If the competition between ARF and p53 for Miz-1 binding truly exists, we would expect that the interaction between ARF and Miz-1 could disrupt or lessen the association between p53 and Miz-1. To verify this hypothesis, MEF (p53À/À and Mdm2À/À) cells were transfected with constant amounts of Miz-1(1 mg) and p53 (2 mg) together with increasing amounts of ARF (0-2 mg). As seen in Figure 6a , with the increase of ARF, less p53 was able to be co-precipitated with Miz-1, suggesting that ARF competes with p53 for binding to Miz-1. In addition, we performed an in vitro GST-pull down-binding assay to further prove our conclusion that p53 and ARF compete for binding to Miz-1. We overexpressed Flag-labeled Miz-1 and ARF in H1299 and purified them first with Flag antibody-coupled agarose beads (Sigma, St Louis, MO, USA), and followed by addition of excess of free 3 Â FLAG peptide (Sigma) to release Flag-ARF or Flag-Miz-1 into supernatant. In doing so, we were able to perform a binding assay between GST-p53 and Flag-Miz-1 with or without Flag-ARF. As shown in Figure 6b , the protein Flag-Miz-1 pulled down by GST-p53 was significantly decreased when the concentration of Flag-ARF was increased, suggesting that ARF and p53 indeed compete for binding to Miz-1 in vitro. If the observation that more binding of Miz-1 to ARF makes less binding of Miz-1 to p53 was true, we would expect that by over-expression of ARF, more p53 will be relieved from Miz-1 repression; in other words, more p53 would be expected to bind to its target promoter such as bax promoter. We then performed a ChIP experiment to confirm this hypothesis. As shown in Figure 6c , with increasing amount of ARF, PCR-enriched p53-bound Bax promoter fragments were increased (lane 8-10), indicating that more p53 binds to Bax promoter region because of less Miz-1 repression. We also performed a luciferase reporter assay using p53-13-p53-Luc report plasmid to further verify this hypothesis. As shown in Figure 6d , the enhanced luciferase relative activity resulted from p53 TA was notably suppressed when Miz-1 was included (lane 4 vs lane 3). However, as ARF was again added, suppressed luciferase activity was shown to be recovered (lane 5 vs lane 4), indicating that ARF inhibits Miz-1's suppression on p53 transcriptional activity. In contrast, ARF was shown to promote p53 TA to some degree in the absence of transfected Miz-1 (lane 6 vs lane 3), which can be explained that in the absence of exogenously expressed Miz-1, ectopically expressed ARF was able to bind more endogenous Miz-1, resulting in less Miz-1 suppression of p53 TA. These results strongly suggested that ARF and p53 compete for binding to Miz-1.
Discussion
ARF suppresses aberrant cell growth in response to oncogenic activation and this process was known to be closely linked to the p53 tumor suppressor pathway. However, an increasing number of studies now suggest that ARF also acts as a tumor suppressor in p53 and/or Mdm2-independent manner. Here, we identified a transcription factor Miz-1 that could interact with p14ARF through its zinc-finger domain (Figures 1a  and 2a) . Although zinc-finger domain is known as DBD, some studies showed that it was also involved in the Figure 6 ARF rescues the suppression of Miz-1 to p53. (a) H1299 cells were co-transfected with fixed amounts of plasmids coding for Flag-Miz-1 and GFP-p53 in combination with increasing amount of pEGFP-ARF. A total of 90% of whole-cell extracts were used for Co-IP using anti-Flag antibody and anti-GFP antibody was used in the western analysis; 10% of each cell extract used for immunoprecipitation was loaded for input. Numbers denote the mean values from the densitometric determination of the protein band. (b) In vitro GST-pull down-binding assay. GST-p53 was expressed in E. coli and purified with glutathione-sepharose beads (BD Biosciences). Over-expressed 3 Â Flag-labeled Miz-1 and ARF in H1299 and purified them first with anti-Flag M2 agarose affinity gel (Sigma), and followed by addition of excess of free 3 Â Flag peptide (Sigma) to release 3 Â Flag-ARF or 3 Â Flag-Miz-1 into supernatant. Role of Miz-1 in ARF-p53 pathway L Miao et al interaction with other proteins (Suzuki et al., 2005; Wanzel et al., 2005) . It is well known that p14ARF is able to activate p53-regulated transcription, and in this study, we show that Miz-1 represses the transcriptional activity of p53, indicating that Miz-1 may antagonize the function of p14ARF in activating p53-mediated transcription. In Mdm2-deficient MEF cells, this Miz-1-mediated p53 transcriptional repression still occurs (Figure 3e ), indicating that an alternative pathway that is independent of p53 stability may exist. Furthermore, our experiments showed that in p14ARF null cell line A549 (human lung adenocarcinoma epithelial cell line), Miz-1 can also inhibit the transcriptional activity of p53, suggesting that the inhibition of p53 transcription activity by Miz-1 is p14ARF independent and possibly a p14ARF downstream event. In other words, Miz-1 alone is able to interfere with p53 transcriptional function. We later found that Miz-1 directly interacts with the DBD of p53, to prevent p53 from binding to its target gene promoter, and thus decrease the p53 transcriptional activity. In the presence of ectopically expressed ARF, however, Miz-1 will bind to ARF, and the p53 transcription repression resulted from Miz-1 will be de-repressed. Our competing IP assay showed that ARF and p53 competitively bind to Miz-1, and ARF could increase p53 transcriptional activity through binding to Miz-1 in the absence of Mdm2, suggesting that Miz-1 acts as a new mediator in ARF-p53 pathway. Our new finding is consistent with some earlier reports that ARF could regulate p53 activity that is independent of Mdm2 function (Chen et al., 2005) and ARF can activate p53 through binding to ARF-binding protein-1(ARFBP-1)/Mule, which was known to be another p53 E3 ligase.
It has been reported that Miz-1 acts as a negative regulator of cell proliferation because it induces expression of cell-cycle inhibitors such as p21 and p15 Staller et al., 2001; Wu et al., 2003; Zhao et al., 2004) . Controversially, Adhikary et al. (2003) reported that Miz-1 is required for early embryonic development during gastrulation. Similarly, Ziegelbauer et al. (2004) reported that the loss of Miz-1 by RNA interference caused cells to accumulate in G1 and led to inhibition of cell proliferation in HepG2 cells. These data indicate that Miz-1 may also have some functions in promoting cell survival or proliferation other than the function in arresting cell growth (Sakurai et al., 2004; Patel and McMahon, 2007) . Interestingly, we found that, different from Puma or Bax promoter, p53-target promoters p21 and Mdm2 showed little, if any, repression by Miz-1 (data not shown), and the mechanism behind this is still unclear at present. Nonetheless, this may be explained that Miz-1-mediated p53 transcriptional repression is gene type or gene function specific and Miz-1 may mainly repress p53 transcription in those apoptosis-related genes, such as Bax or Puma.
According to our results, we proposed a model to explain how the Miz-1 regulates the ARF-p53 pathway ( Figure 6e ). As shown in Figure 6e , Miz-1 interacts with p53 through its DBD domain, preventing p53 from binding to its target promoter region and repressing p53-regulated transcription. However, when ARF is in excess, it will compete with p53 to interact with Miz-1, more p53 will then be released from the p53-Miz-1 complex and is able to re-activate the gene transcription.
Materials and methods
Plasmids
Miz-1 shRNA sequence was cloned into plasmid pshRNA (kindly provided by Dr Zhiyin Song, Division of Biology, California Institute of Technology, Pasadena, CA, USA). The primers used for constructing pshRNA for the purpose of silencing Miz-1 are as follow:
0 .
Reagents and antibodies
The following antibodies were used in this study: monoclonal antibodies anti-Miz-1(H190), anti-Mdm2(SMP14, D12), and anti-Bax(2D2) were purchased form Santa Cruz Biotechnology (Santa Cruz, CA, USA); anti-p53 (Ab-2 and Ab-6) and anti-p14ARF (NA70) were obtained from Calbiochem (San Diego, CA, USA); anti-GFP (BD Biosciences, Palo Alto, CA, USA); anti-Flag (Sigma); anti-b-actin and anti-PUMA (Abcam, Cambridge, UK).The reagents used in this paper were: Dox and MG132 (Sigma), Lipofectmine 2000 and Oligofectmine (Invitrogen, Carlsbad, CA, USA). The siRNA for Miz-1(sc-38085) and control (sc-37007) were purchased from Santa Cruz Biotechnology.
Luciferase reporter assays H1299, A549, or MEF cells were transiently transfected with the indicated plasmids using Lipofectamine 2000 (Invitrogen). The luciferase reporter assay was performed using the DualLuciferase reporter assay system (Promega, Madison, WI, USA) according to the manufacturer 0 s instructions. Quantification of luciferase activity and calculation of relative ratios were carried out manually with a luminometer (LUMAT LB9509, Berthold Technologies, Thoiry, France). Transfection efficiency was normalized on the basis of the Renilla luciferase activity.
Yeast two-hybrid screening Full-length p14ARF was amplified by PCR and was cloned into the yeast expression plasmid pGBDT7 (Clontech, Mountain View, CA, USA), to fuse the GAL4 protein as bait. Human Brain Library (Clontech) was used. The screen for the interacting protein candidates by yeast two-hybrid system was performed according to the manufacturer's instructions (Clontech).
Cell culture and transient transfection All cell lines (H1299 cell, A549 cell, HeLa cell, MEF cell, HepG2 cell) were cultured in Dulbecco's modified Eagle medium (Invitrogen) supplemented with 10% fetal bovine serum (Invitrogen), 2 mm glutamine, 100 mg/ml penicillin, and Co-IP and western blotting Transfected cells were harvested 24 or 48 h post-transfection and lysed in 20 mM Tris-HCl (pH7.5), 1 mM EDTA, 150 mM NaCl, 1 mM phenylmethylsulfonyl fluoride, 0.5% NP-40, and protease inhibitors (Roche, Basel, Switzerland). Cell lysates were incubated on ice for 30 min, and the extracts were centrifuged at 18000 g (4 1C) for 20 min to pellet cell debris. Lysates were incubated overnight at 4 1C with 10 ml protein A/G agarose (Prince, Rockford, IL, USA) that was presaturated with the indicated antibody. The beads were washed vigorously three times with lysis buffer before boiling in sample loading buffer at 100 1C for 5 min. Proteins were resolved by 12-15% sodium dodecyl sulfate-polyacrylamide gel (SDS-PAGE) and subjected to immunoblot analysis using the indicated antibodies. Proteins were visualized by an enhanced chemiluminescence method (Amersham).
Reverse transcription polymerase chain reaction Total cellular RNA was prepared using the SV Total RNA Isolation System (Promega). The yield and purity of the RNA sample were determined by ultraviolet spectrometry using the DU 640 Nucleic Acid and Protein Analyser (Beckman Coulter). Two micrograms of total RNA were reverse transcribed using the TaKaRa One
Step RNA PCR kit (TaKaRa Bio Inc., Otsu, Shiga, Japan). In both RT and PCR steps, the reaction reagents were prepared as master mixtures and then aliquotted. PCR primers were designed to amplify the sequence for the intracellular domain of the Miz-1. The housekeeping gene, b-actin, was amplified as an internal control. The following are the specific primers for b-actin (forward, 5 0 -GACCTGACTGACTACCTCATGAAGAT-3 0 ; reverse: 5 0 -GTCACACTTCATGATGGAGTTGAAGG-3 0 ) and Miz-1 (forward, 5 0 -CGATGGACTTTCCCCAGCACA GCCAG-3 0 ; reverse: 5 0 -CGAAGCTTCTCGAGCTCGGCA GGAGGGGGACA-3 0 ).
ChIP assay H1299 cells were transfected with the indicated plasmids for 24 h and cells were cross-linked with 1% formaldehyde for 10 min. ChIP assay was performed using anti-p53 (Calbiochem) and the ChIP assay kit (Upstate, Millipore, Temecula, CA, USA) according to the manufacturer's protocol. Anti-GFP (Zymed Laboratories, Inc., San Diego) and anti-mouse IgG (Upstate) were used as controls. The primers used in this study were Bax (forward, 5 0 -TAATCCCAGCGCTTTGGA AG-3 0 ; reverse, 5 0 -TGCAGAGACCTGGATCTAGCAA-3 0 ) and PUMA (forward, 5 0 -GCGAGACTGTGGCCTTGTGT-3 0 ; reverse, 5 0 -CGTTCC AGGGTCCACAAAGT-3 0 ).
In vitro GST-pull down-binding assay GST-p53 was expressed in Escherichia coli and purified with glutathione-sepharose beads (BD Biosciences). 3 Â Flaglabeled Miz-1 and ARF were over-expressed in H1299 and were purified first with anti-Flag M2 agarose affinity gel (Sigma), and followed by addition of excess of free 3 Â Flag peptide (Sigma) to competitive elution 3 Â Flag-ARF or 3 Â Flag-Miz-1 into supernatant; 30 ng GST-p53-coupled beads were incubated with 10 ng purified 3 Â Flag-Miz-1 for binding assay for 6 h without or with increased Flag-ARF, and then washed three times with binding buffer and the final products were checked by anti-Miz-1 antibody.
